Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin’s Lymphoma (NHL)

Copyright: © 2013 Uckun FM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. In recent years new biotherapy options have emerged for patients with B-lineage Non-Hodgkin’s Lymphoma (NHL). A series of novel mAbs with specificity for a variety of surface antigens are currently under evaluation. These include anti-CD20 mAb (ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, ublituximab), antiCD19 mAb (MOR208), anti-CD22 mAbs (epratuzumab, inotuzumab ozogamicin) and anti-CD16/CD30 mAb (TandAb® AFM13) [1-12].